NeoGenomics Names Warren Stone Chief

NeoGenomics announced a leadership change on October 5, 2026. NeoGenomics named President and COO Warren Stone CEO effective January 4, 2027, with Tony Zook becoming Executive Chair and the company emphasizing strategic continuity.

What changed

Warren Stone was named Chief Executive Officer. Tony Zook, the current CEO, will assume the role of Executive Chair when Stone becomes CEO and will continue to work in close alignment with Stone and the Board.

Leader: Warren Stone
Role: Chief Executive Officer
Effective: January 4, 2027
Announcement date: October 5, 2026

Leadership background

Stone, 54, has more than three decades of life sciences and diagnostics leadership experience, including senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA. Since joining NeoGenomics in 2022, he has held roles of increasing responsibility, including President of Clinical Services and Chief Commercial Officer, most recently serving as President and Chief Operating Officer.

The mandate

In the release, Zook said the transition emphasizes strategic continuity and a consistent strategy for durable, profitable growth at NeoGenomics, and he cited Stone’s work on commercial expansion and customer impact, new product introductions, and Lab of the Future initiatives.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

NeoGenomics